Piette EW, Werth VP. Dapsone in the management of the autoimmune bullous diseases. Dermatol Clin 2012; 29(4): 561-4.
Kamal KS, Shyam CC, Jitendra S, Deep CR, Sanjay M, Madhu MG. Dapsone-induced pure red cell aplasia and cholestatic jaundice: A new experience for diagnosis and management. J Res Pharm Pract 2016; 5(3): 215-8.
Kolar VV, Karyampundi A, Tarun KD. Dapsone hypersensitivity syndrome: A rare life threatening complication of dapsone therapy. J Pharmacol Pharmacother 2013; 4(2): 158-60.
So YC, Ho YH, Jung HL, Jae SP, Min SJ. Severe dapsone hypersensitivity syndrome in a child. Korean J Pediatr 2013; 56(6): 260-4.
Mary G. An unusual case of dapsone syndrome. Indian Dermatol Online J 2011; 2(2): 88-90.
Na W, Leela P, Hong L, Furen Z. A review on dapsone hypersensitivity syndrome among Chinese patients with an emphasis on preventing adverse drug reaction with genetic testing. Am J Trop Med Hyg 2017; 96(5): 1014-8.
Coleman MD, Breckenridge AM, Park BK. Bioactivation of dapsone to a cytotoxic metabolite by human hepatic microsomal enzymes. Br J Clin Pharmacol 1989; 28: 389-95.
Tempark T, Satapornpong P, Rerknimitr P, et al. Dapsone-induced severe cutaneous adverse drug reactions are strongly linked with HLA-B*13: 01 allele in the Thai population. Pharmacogenet Genomics 2017; 27: 429-37.
Semaan GK, Bhuvana G, Dima NN, David SC, Guhan K. The dapsone hypersensitivity syndrome revisited: A potentially fatal multisystem disorder with prominent hepatopulmonary manifestations. J Occup Med Toxicol 2006; 1: 9.
Wozel G, Blasum C. Dapsone in dermatology and beyond. Arch Dermatol Res 2014; 306(2): 103-24.